PCYC Big Player At 2014 ASCO * Presenting Phase III Resontae ** read
Pharmacyclics (PCYC) Story Unchanged Following Q1 Report; Roth Reiterates at 'Buy'
The Street Insider
May 5, 2014 11:37 AM
We look forward to the end of the month when the initial data from the Phase III RESONTAE study of single-agent Imbruvica vs. ofatumumab will be presented at ASCO.